Examining the relationship between COVID-19 vaccines and recall rates in breast screening.

IF 1.5 Q3 HEALTH CARE SCIENCES & SERVICES
Lorena Squillace, Lorenzo Pizzi, Angela Chiereghin, Carmen Bazzani, Gianni Saguatti, Alfredo Tafà, Lorenzo Roti, Francesca Mezzetti
{"title":"Examining the relationship between COVID-19 vaccines and recall rates in breast screening.","authors":"Lorena Squillace, Lorenzo Pizzi, Angela Chiereghin, Carmen Bazzani, Gianni Saguatti, Alfredo Tafà, Lorenzo Roti, Francesca Mezzetti","doi":"10.7416/ai.2025.2699","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>It has been observed that women vaccinated against coronavirus disease 2019 (COVID-19) may show axillary lymphadenopathy at screening mammogram, which may become suspicious for malignancy, leading to an increased recall rate for further diagnostic evaluations and a higher number of false-positive results, as well as considerable emotional distress for the women involved.</p><p><strong>Study design: </strong>The study aimed to assess the incidence of doubt/positive results in the 1st level mammogram among women who received a COVID-19 vaccine within 4 weeks before mammogram, compared to unvaccinated women. Further aims included the analysis of the distribution of doubt/positive 1st level screening mammogram results according to different women-related and diagnostic work-up-related characteristics, and the evaluation of the incidence of false-positive results observed at the 2nd level.</p><p><strong>Methods: </strong>The cohort study was carried out by retrospectively reviewing electronic data records related to the breast screening program of the Local Health Authority of Bologna in 2021 concerning women between 45 and 74 years old. Excluded were the women outside the age range, with prior breast cancer history, or receiving COVID-19 vaccination more than 4 weeks before the mammogram.</p><p><strong>Results: </strong>A total of 43,856 (mean age 56.6 ± 8.7) women met the study's inclusion criteria. Among all enrolled women, the recall rate was 5.5% (N=2,394). There were no statistically significant differences in doubt/positive results between vaccinated within 4 weeks before the mammogram and unvaccinated women (5.5% versus 5.4%, p=0.649). However, those who received the Pfizer vaccine showed a significantly higher rate of doubt/positive results.</p><p><strong>Conclusions: </strong>Healthcare professionals' awareness of vaccine records and educating patients about rare adverse effects can help prevent unnecessary biopsies, interventions, and changes in patient management. Further research is needed to confirm our findings.</p>","PeriodicalId":7999,"journal":{"name":"Annali di igiene : medicina preventiva e di comunita","volume":" ","pages":"666-675"},"PeriodicalIF":1.5000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annali di igiene : medicina preventiva e di comunita","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7416/ai.2025.2699","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/10 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: It has been observed that women vaccinated against coronavirus disease 2019 (COVID-19) may show axillary lymphadenopathy at screening mammogram, which may become suspicious for malignancy, leading to an increased recall rate for further diagnostic evaluations and a higher number of false-positive results, as well as considerable emotional distress for the women involved.

Study design: The study aimed to assess the incidence of doubt/positive results in the 1st level mammogram among women who received a COVID-19 vaccine within 4 weeks before mammogram, compared to unvaccinated women. Further aims included the analysis of the distribution of doubt/positive 1st level screening mammogram results according to different women-related and diagnostic work-up-related characteristics, and the evaluation of the incidence of false-positive results observed at the 2nd level.

Methods: The cohort study was carried out by retrospectively reviewing electronic data records related to the breast screening program of the Local Health Authority of Bologna in 2021 concerning women between 45 and 74 years old. Excluded were the women outside the age range, with prior breast cancer history, or receiving COVID-19 vaccination more than 4 weeks before the mammogram.

Results: A total of 43,856 (mean age 56.6 ± 8.7) women met the study's inclusion criteria. Among all enrolled women, the recall rate was 5.5% (N=2,394). There were no statistically significant differences in doubt/positive results between vaccinated within 4 weeks before the mammogram and unvaccinated women (5.5% versus 5.4%, p=0.649). However, those who received the Pfizer vaccine showed a significantly higher rate of doubt/positive results.

Conclusions: Healthcare professionals' awareness of vaccine records and educating patients about rare adverse effects can help prevent unnecessary biopsies, interventions, and changes in patient management. Further research is needed to confirm our findings.

探讨COVID-19疫苗与乳腺筛查召回率的关系
背景:据观察,接种了2019冠状病毒病(COVID-19)疫苗的女性在筛查乳房x光检查时可能出现腋窝淋巴结病变,可能会怀疑是恶性肿瘤,导致进一步诊断评估的召回率增加,假阳性结果增多,并给相关女性带来相当大的情绪困扰。研究设计:本研究旨在评估在乳房x光检查前4周内接种COVID-19疫苗的妇女与未接种疫苗的妇女相比,在第一级乳房x光检查中出现怀疑/阳性结果的发生率。进一步的目的包括根据不同的女性相关和诊断性工作相关特征分析可疑/阳性的一级筛查乳房x线检查结果的分布,并评估第二级观察到的假阳性结果的发生率。方法:回顾性回顾博洛尼亚地方卫生当局2021年45 - 74岁女性乳房筛查项目相关电子数据记录,开展队列研究。排除年龄范围以外、既往有乳腺癌病史或在乳房x光检查前4周以上接受COVID-19疫苗接种的妇女。结果:共有43,856名女性(平均年龄56.6±8.7岁)符合研究的纳入标准。在所有入组的女性中,召回率为5.5% (N= 2394)。在乳房x光检查前4周内接种疫苗的妇女和未接种疫苗的妇女之间,怀疑/阳性结果无统计学意义差异(5.5%对5.4%,p=0.649)。然而,那些接受辉瑞疫苗的人表现出明显更高的怀疑/阳性结果率。结论:卫生保健专业人员对疫苗记录的了解和对患者进行罕见不良反应的教育有助于预防不必要的活检、干预和患者管理的改变。需要进一步的研究来证实我们的发现。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Annali di igiene : medicina preventiva e di comunita
Annali di igiene : medicina preventiva e di comunita HEALTH CARE SCIENCES & SERVICES-
CiteScore
3.40
自引率
0.00%
发文量
69
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信